Non-Hodgkin Lymphoma

Bexxar following chemotherapy produced high rate of response

Published in Cancer Weekly, October 21st, 2003

A novel therapeutic approach of Bexxar (Tositumomab and Iodine I-131 Tositumomab) following chemotherapy has been shown to produce a high rate of response in patients with advanced follicular non-Hodgkin lymphoma (NHL), according to the results of a study published in the September 1, 2003, issue of Blood.

The phase II clinical study assessed a two-part treatment consisting of CHOP chemotherapy (a combination-chemotherapy regimen) followed by the Bexxar therapeutic regimen. This is the first fully published study of a combination treatment involving chemotherapy and radioimmunotherapy in the first-line treatment of follicular NHL. The treatment produced an...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-10-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry